These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 32325420)
21. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy. Teixeira N; Mourits MJ; Oosterwijk JC; Fakkert IE; Absalom AR; Bakker SJL; van der Meer P; de Bock GH Fam Cancer; 2019 Jan; 18(1):19-27. PubMed ID: 29881922 [TBL] [Abstract][Full Text] [Related]
22. Uptake and efficacy of bilateral risk reducing surgery in unaffected female Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438 [TBL] [Abstract][Full Text] [Related]
23. Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy. van Verschuer VM; Heemskerk-Gerritsen BA; van Deurzen CH; Obdeijn IM; Tilanus-Linthorst MM; Verhoef C; Schmidt MK; Koppert LB; Hooning MJ; Seynaeve C Cancer Biol Ther; 2014 Apr; 15(4):371-9. PubMed ID: 24423863 [TBL] [Abstract][Full Text] [Related]
24. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations. Solsky I; Chen J; Rebbeck TR Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993 [TBL] [Abstract][Full Text] [Related]
25. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. Kim D; Kang E; Hwang E; Sun Y; Hwang Y; Yom CK; Kim K; No JH; Kim YB; Kim SW Fam Cancer; 2013 Dec; 12(4):621-8. PubMed ID: 23504064 [TBL] [Abstract][Full Text] [Related]
26. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study. Terra L; Lee Meeuw Kjoe PR; Agelink van Rentergem JA; Beekman MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mourits MJE; van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; van der Wall E; van Leeuwen FE; Schagen SB BJOG; 2023 Jul; 130(8):968-977. PubMed ID: 36715559 [TBL] [Abstract][Full Text] [Related]
27. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902 [TBL] [Abstract][Full Text] [Related]
28. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in Gaba F; Blyuss O; Tan A; Munblit D; Oxley S; Khan K; Legood R; Manchanda R Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900415 [TBL] [Abstract][Full Text] [Related]
29. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828 [TBL] [Abstract][Full Text] [Related]
30. Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy. Chan LN; Chen LM; Goldman M; Mak JS; Bauer DC; Boscardin J; Schembri M; Bae-Jump V; Friedman S; Jacoby VL Obstet Gynecol; 2023 Jul; 142(1):160-169. PubMed ID: 37290104 [TBL] [Abstract][Full Text] [Related]
31. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up. Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273 [TBL] [Abstract][Full Text] [Related]
32. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice? Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307 [TBL] [Abstract][Full Text] [Related]
33. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Cohen JV; Chiel L; Boghossian L; Jones M; Stopfer JE; Powers J; Rebbeck TR; Nathanson KL; Domchek SM Fam Cancer; 2012 Mar; 11(1):69-75. PubMed ID: 21898151 [TBL] [Abstract][Full Text] [Related]
34. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial. Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085 [TBL] [Abstract][Full Text] [Related]
35. Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk. Terry MB; Daly MB; Phillips KA; Ma X; Zeinomar N; Leoce N; Dite GS; MacInnis RJ; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; Weideman PC; Glendon G; Buchsbaum R; Andrulis IL; John EM; Buys SS; Hopper JL J Natl Cancer Inst; 2019 Mar; 111(3):331-334. PubMed ID: 30496449 [TBL] [Abstract][Full Text] [Related]
36. Factors associated with intentions for breast cancer risk management: Does risk group matter? Conley CC; Agnese DM; Vadaparampil ST; Andersen BL Psychooncology; 2019 May; 28(5):1119-1126. PubMed ID: 30889627 [TBL] [Abstract][Full Text] [Related]
37. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE; J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028 [TBL] [Abstract][Full Text] [Related]
38. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Heemskerk-Gerritsen BAM; Jager A; Koppert LB; Obdeijn AI; Collée M; Meijers-Heijboer HEJ; Jenner DJ; Oldenburg HSA; van Engelen K; de Vries J; van Asperen CJ; Devilee P; Blok MJ; Kets CM; Ausems MGEM; Seynaeve C; Rookus MA; Hooning MJ Breast Cancer Res Treat; 2019 Oct; 177(3):723-733. PubMed ID: 31302855 [TBL] [Abstract][Full Text] [Related]
39. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175 [TBL] [Abstract][Full Text] [Related]
40. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy. Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]